https://scholars.lib.ntu.edu.tw/handle/123456789/634901
Title: | Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma | Authors: | Doki, Yuichiro Ajani, Jaffer A Kato, Ken Xu, Jianming Wyrwicz, Lucjan Motoyama, Satoru Ogata, Takashi Kawakami, Hisato CHIH-HUNG HSU Adenis, Antoine El Hajbi, Farid Di Bartolomeo, Maria Braghiroli, Maria I Holtved, Eva Ostoich, Sandra A Kim, Hye R Ueno, Masaki Mansoor, Wasat Yang, Wen-Chi Liu, Tianshu Bridgewater, John Makino, Tomoki Xynos, Ioannis Liu, Xuan Lei, Ming Kondo, Kaoru Patel, Apurva Gricar, Joseph Chau, Ian Kitagawa, Yuko |
Issue Date: | 3-Feb-2022 | Journal Volume: | 386 | Journal Issue: | 5 | Source: | The New England journal of medicine | Abstract: | First-line chemotherapy for advanced esophageal squamous-cell carcinoma results in poor outcomes. The monoclonal antibody nivolumab has shown an overall survival benefit over chemotherapy in previously treated patients with advanced esophageal squamous-cell carcinoma. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634901 | ISSN: | 00284793 | DOI: | 10.1056/NEJMoa2111380 |
Appears in Collections: | 腫瘤醫學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.